Long-Acting Injectables for HIV Antiretroviral Therapy
Resource updated 04/12/2024
Resource updated 04/12/2024
Blog updated 12/22/2022
Resource updated 12/19/2023
Resource updated 05/11/2023
Resource updated 04/07/2023
Among people with HIV who also inject drugs, an estimated 80 to 90 percent are coinfected with Hepatitis C (HCV.) This panel will provide updates on screening and referral activities and demonstrate how community and city partners are overcoming barriers to HCV care among PWID.
Resource (Conference Presentation) updated 09/14/2023
Module (factsheet) quick reference guide to providers and staff on frequently asked questions and answers regarding buprenorphine treatment. Chapter in the curriculum, Integration of Buprenorphine into HIV Primary Care Settings.
Resource updated 09/14/2023
Resource updated 09/14/2023
Review of opioid addiction treatment, specifically buprenorphine, and its variance from methadone and naltrexone opioid addiction treatment options. Chapter in the curriculum, Integration of Buprenorphine into HIV Primary Care Settings.
Module to assess provider community's awareness and perspectives on opioid use risks among clients as a decision point on whether to undertake integration of buprenorphine use within the HIV clinic. Chapter in the curriculum, Integration of Buprenorphine into HIV Primary Care Settings.
Resources on opioid treatment. Part of the curriculum, Integration of Buprenorphine into HIV Primary Care Settings
Resource updated 04/07/2023
Overview of addiction and medication-assisted addiction treatment, including buprenorphine and methadone. Chapter in the curriculum, Integration of Buprenorphine into HIV Primary Care Settings.
Review of the content (e.g., training design, handouts) of the curriculum to educate staff and other stakeholders on how to replicate models of care to engage and retain hard-to-reach populations into HIV medical care. Part of the tools in Innovative Approaches to Engaging Hard-to-Reach Populations Living with HIV/AIDS into Care.